129 related articles for article (PubMed ID: 28874808)
21. Preoperative serum levels of YKL 40 and CA125 as a prognostic indicators in patients with endometrial cancer.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Wagrodzki M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():141-147. PubMed ID: 28624692
[TBL] [Abstract][Full Text] [Related]
22. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
23. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
24. Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease.
Sebastianelli A; Renaud MC; Grégoire J; Roy M; Plante M
J Obstet Gynaecol Can; 2010 Sep; 32(9):856-860. PubMed ID: 21050518
[TBL] [Abstract][Full Text] [Related]
25. [Preoperative platelet count as index of the grading in endometrial carcinoma].
Giannella L; Menozzi G; Di Monte I; Venturini P; De Pace V; Boselli F; Ternelli G; Jasonni VM
Minerva Ginecol; 2008 Aug; 60(4):273-9. PubMed ID: 18560341
[TBL] [Abstract][Full Text] [Related]
26. The role of HE4 in differentiating benign and malignant endometrial pathology.
Gąsiorowska E; Magnowska M; Iżycka N; Warchoł W; Nowak-Markwitz E
Ginekol Pol; 2016; 87(4):260-4. PubMed ID: 27321096
[TBL] [Abstract][Full Text] [Related]
27. External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer.
Koskas M; Uzan J; Vanderstraeten A; Vergote I; Amant F
Gynecol Oncol; 2016 Jul; 142(1):83-88. PubMed ID: 27174876
[TBL] [Abstract][Full Text] [Related]
28. Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer.
Cymbaluk-Płoska A; Chudecka-Głaz A; Pius-Sadowska E; Sompolska-Rzechuła A; Chudecka K; Bulsa M; Machaliński B; Menkiszak J
Dis Markers; 2017; 2017():6589262. PubMed ID: 29089666
[TBL] [Abstract][Full Text] [Related]
29. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract][Full Text] [Related]
30. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.
Zanotti L; Bignotti E; Calza S; Bandiera E; Ruggeri G; Galli C; Tognon G; Ragnoli M; Romani C; Tassi RA; Caimi L; Odicino FE; Sartori E; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2012 Dec; 50(12):2189-98. PubMed ID: 23096757
[TBL] [Abstract][Full Text] [Related]
31. [Value of gynecological cytology and CA 125 level for the prediction of extrauterine malignancy in endometrial cancer].
Brassard L; Bessette P
J Obstet Gynaecol Can; 2012 Jul; 34(7):657-63. PubMed ID: 22742485
[TBL] [Abstract][Full Text] [Related]
32. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.
Angioli R; Capriglione S; Scaletta G; Aloisi A; Miranda A; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2016 Apr; 37(4):4973-8. PubMed ID: 26531723
[TBL] [Abstract][Full Text] [Related]
33. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4.
Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
[TBL] [Abstract][Full Text] [Related]
34. Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study.
Fanfani F; Restaino S; Cicogna S; Petrillo M; Montico M; Perrone E; Radillo O; De Leo R; Ceccarello M; Scambia G; Ricci G
Int J Gynecol Cancer; 2017 Jul; 27(6):1200-1205. PubMed ID: 28557834
[TBL] [Abstract][Full Text] [Related]
35. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.
Minar L; Klabenesova I; Jandakova E; Zlamal F; Bienertova-Vasku J
J Obstet Gynaecol Res; 2015 Oct; 41(10):1644-52. PubMed ID: 26223178
[TBL] [Abstract][Full Text] [Related]
37. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
[No Abstract] [Full Text] [Related]
38. Detection of circulating tumour cells may add value in endometrial cancer management.
Ni T; Sun X; Shan B; Wang J; Liu Y; Gu SL; Wang YD
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():1-4. PubMed ID: 27756035
[TBL] [Abstract][Full Text] [Related]
39. Anti-Müllerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial cancer.
Dogan NU; Kerimoglu OS; Karabagli P; Pekin A; Yilmaz SA; Incesu F; Celik C
J Obstet Gynaecol; 2015 Feb; 35(2):178-82. PubMed ID: 25111828
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
Pasanen A; Loukovaara M; Tuomi T; Bützow R
Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
